NASDAQ:BCRX

Biocryst Pharmaceuticals Stock Insider Trading

etoro logo Buy BCRX
*Your capital is at risk
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026

BioCryst Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -8.99. In total, the insiders bought 6.54M and sold 1.09M BCRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-8.99
Buy 6.54M shares
Sell 1.09M shares
80% Buy Activity
Negligible or No Correlation
Sell Signal Low Confidence
May 13, 2026

Analysis Breakdown:

  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Feb 27, 2026
Buy
Common Stock
A-Award
Milne Jill C.
Director
Director 528
Value: $5K
Feb 27, 2026
Buy
Common Stock
A-Award
Stonehouse Jon P
Director
Director 421
Value: $4K
Jan 23, 2026
Buy
Automatic Stock Option Grant
A-Award
Milne Jill C.
Director
Director 26 684
Value: $181.2K
Jan 23, 2026
Buy
Common Stock
A-Award
Milne Jill C.
Director
Director 12 272
Value: $83.3K
Jan 23, 2026
Buy
Common Stock
A-Award
Milne Jill C.
Director
Director 2 582
Value: $22.1K
Jan 23, 2026
Buy
Common Stock
J-Other
Milne Jill C.
Director 0
Value: $0
Jan 01, 2026
Buy
Common Stock
Dullinger Ronald
Chief Commercial Officer
Officer 0
Value: $0
Dec 22, 2025
Sell
Common Stock
S-Sale
Barnes Alane P
Chief Legal Officer
Officer 21 773
Value: $166.6K
Dec 22, 2025
Buy
Common Stock
M-Exempt
Gayer Charles K
President And Cco
CEO / President 50 000
Value: $275.5K
Dec 22, 2025
Buy
Common Stock
M-Exempt
Gayer Charles K
President And Cco
CEO / President 10 091
Value: $50.9K
Dec 22, 2025
Buy
Common Stock
M-Exempt
Gayer Charles K
President And Cco
CEO / President 14 142
Value: $45.5K
Dec 22, 2025
Buy
Emp. Stock Option (Right to Buy)
M-Exempt
Gayer Charles K
President And Cco
CEO / President 10 091
Value: $50.9K
Dec 22, 2025
Buy
Emp. Stock Option (Right to Buy)
M-Exempt
Gayer Charles K
President And Cco
CEO / President 50 000
Value: $275.5K
Dec 22, 2025
Buy
Emp. Stock Option (Right to Buy)
M-Exempt
Gayer Charles K
President And Cco
CEO / President 14 142
Value: $45.5K
Dec 19, 2025
Buy
Emp. Stock Option (Right to Buy)
Dullinger Ronald
Chief Commercial Officer
Officer 68 500
Value: $506.2K
Dec 19, 2025
Sell
Common Stock
F-InKind
Stonehouse Jon P
Chief Executive Officer
CEO / President 61 793
Value: $457.9K
Dec 19, 2025
Sell
Common Stock
F-InKind
Barnes Alane P
Chief Legal Officer
Officer 16 902
Value: $125.2K
Dec 19, 2025
Sell
Common Stock
F-InKind
Gayer Charles K
President And Cco
CEO / President 11 477
Value: $85.0K
Dec 18, 2025
Buy
Common Stock
G-Gift
Stonehouse Jon P
Chief Executive Officer
CEO / President 10 000
Value: $72.9K
Dec 18, 2025
Sell
Common Stock
G-Gift
Stonehouse Jon P
Chief Executive Officer
CEO / President 20 000
Value: $0
Dec 17, 2025
Buy
Emp. Stock Option (Right to Buy)
A-Award
Gayer Charles K
President And Cco
CEO / President 986 950
Value: $7.04M
Dec 17, 2025
Buy
Common Stock
A-Award
Gayer Charles K
President And Cco
CEO / President 471 000
Value: $3.36M
Dec 17, 2025
Buy
Common Stock
A-Award
Barnes Alane P
Chief Legal Officer
Officer 121 700
Value: $867.7K
Dec 17, 2025
Buy
Emp. Stock Option (Right to Buy)
A-Award
Barnes Alane P
Chief Legal Officer
Officer 255 050
Value: $1.82M
Dec 17, 2025
Buy
Emp. Stock Option (Right to Buy)
A-Award
Ghias Babar
Chief Financial Officer
C-Suite Officer 355 050
Value: $2.53M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT BIOCRYST PHARMACEUTICALS
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE